Etazolate

Drug Profile

Etazolate

Alternative Names: EHT 202; EHT-0202

Latest Information Update: 21 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ExonHit Therapeutics
  • Developer Diaxonhit; ExonHit Therapeutics
  • Class Antiarrhythmics; Antipsychotics; Nicotinic-acids; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; GABA A receptor modulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease; Retinal disorders; Vascular dementia

Most Recent Events

  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 15 Mar 2011 Etazolate is available for licensing as of 15 Mar 2011. http://www.exonhit.com/
  • 30 Oct 2009 Efficacy & adverse events data from a phase IIa trial in Alzheimer's disease presented at the 2nd Conference of Clinical Trials on Alzheimer's Disease (CTAD-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top